ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
66,283.53
0.14%
S&P 500
5,431.60
-0.04%
Dow Jones
38,589.16
-0.15%
US Dollar vs Yen
157.405
0.00%
Brent Oil
82.275
0.00%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Madrigal Pharmaceuticals Inc (MDGL)

  7. Madrigal Pharmaceuticals Inc (MDGL) ニュース

MDGL

Madrigal Pharmaceuticals (MDGL)

Madrigal Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:MDGL
日付受信時刻ニュースソース見出しコード企業名
2024/06/1510 : 44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/06/1510 : 44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/06/1506 : 17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/06/1505 : 37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/06/1406 : 53Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/06/1306 : 03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/06/1206 : 39Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/06/0707 : 48Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/06/0621 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL CongressNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/06/0521 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/05/2921 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL CongressNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/05/2410 : 36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/05/0805 : 36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/05/0805 : 34Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/05/0805 : 29Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/05/0722 : 00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/05/0720 : 06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/05/0720 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/04/2505 : 00GlobeNewswire Inc.Madrigal Statement on the Passing of Dr. Stephen HarrisonNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/04/2321 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/04/1705 : 05GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/04/0921 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver FibrosisNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/04/0405 : 05GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/03/1912 : 58GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public OfferingNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/03/1905 : 04GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Proposed Public OfferingNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/03/1520 : 30IH Market NewsAdobe Stock Drops Following Below-Estimate Projections, Cardlytics Surges with Unexpected Profit, and More NewsNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/03/1505 : 15GlobeNewswire Inc.Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver FibrosisNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/03/0706 : 05GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/03/0522 : 00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver FibrosisNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/2821 : 10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MDGLMadrigal Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MDGL

最近閲覧した銘柄

NYSE
KO
Coca Cola
AMEX
XLV
Health Care Select Sector
NASDAQ
MSFT
Microsoft
AMEX
SPY
SPDR S&P 500
USI
USTECH100
US Tech 100
NASDAQ
GOOGL
Alphabet
NYSE
DIS
Walt Disney
NASDAQ
AAPL
Apple
USOTC
BASFY
BASF (QX)
CCOM
US100
US Tech 100
NYSE
XOM
Exxon Mobil
PM
XAUUSD
Gold vs US Dollar
FX
USDGBP
US Dollar vs Sterling
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
TSLA
Tesla
NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有